Yes, Heron Therapeutics (NASDAQ: HRTX) qualifies as a penny stock, trading well below the traditional five-dollar threshold at a fraction of a dollar per share. Penny stocks are characterized by low share prices, smaller overall market capitalizations, and elevated intraday volatility, which can attract speculative retail trading interest alongside substantial liquidity risks. Investors evaluating micro-cap equities like HRTX must perform rigorous fundamental analysis and account for potential regulatory or listing compliance pressures.